Crosstalk between ROS-inflammatory gene expression axis in the progression of lung disorders
Naunyn-Schmiedeberg s Archives of Pharmacology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 28, 2024
Language: Английский
Involvement of osteopontin, EpCAM, estrogen receptor-alpha, and carbonic anhydrase IX protein in managing lung cancer via Berberine-loaded liquid crystalline nanoparticles
Pathology - Research and Practice,
Journal Year:
2023,
Volume and Issue:
253, P. 154971 - 154971
Published: Nov. 24, 2023
Language: Английский
18-β-Glycyrrhetinic acid encapsulated PLGA nanoparticles attenuate lung cancer proliferation and migration
Journal of Drug Delivery Science and Technology,
Journal Year:
2024,
Volume and Issue:
95, P. 105523 - 105523
Published: March 9, 2024
Language: Английский
Revolutionizing lung health: Exploring the latest breakthroughs and future prospects of synbiotic nanostructures in lung diseases
Chemico-Biological Interactions,
Journal Year:
2024,
Volume and Issue:
395, P. 111009 - 111009
Published: April 17, 2024
The
escalating
prevalence
of
lung
diseases
underscores
the
need
for
innovative
therapies.
Dysbiosis
in
human
body
microbiome
has
emerged
as
a
significant
factor
these
diseases,
indicating
potential
role
synbiotics
restoring
microbial
equilibrium.
However,
effective
delivery
to
target
site
remains
challenging.
Here,
we
aim
explore
suitable
nanoparticles
encapsulating
tailored
applications
diseases.
Nanoencapsulation
prominent
strategy
address
challenges
this
context.
Through
comprehensive
review,
assess
facilitating
synbiotic
and
their
structural
adaptability
purpose.
Our
review
reveals
that
such
nanocellulose,
starch,
chitosan
exhibit
high
encapsulation.
These
offer
flexibility
structure
design
synthesis,
making
them
promising
candidates
addressing
Furthermore,
our
analysis
highlights
synbiotics,
when
compared
probiotics
alone,
demonstrate
superior
anti-inflammatory,
antioxidant,
antibacterial
anticancer
activities.
This
nanoparticle-encapsulated
targeted
therapeutic
approach
contributing
valuable
insights
into
nanomedicine
revolutionizing
treatment
strategies
respiratory
conditions,
ultimately
paving
way
future
advancements
field.
Language: Английский
Exploring the state-of-art of lipid nanomedicines for obstructive pulmonary diseases
Elsevier eBooks,
Journal Year:
2025,
Volume and Issue:
unknown, P. 191 - 231
Published: Jan. 1, 2025
Language: Английский
Liposomal curcumin inhibits cigarette smoke induced senescence and inflammation in human bronchial epithelial cells
Pathology - Research and Practice,
Journal Year:
2024,
Volume and Issue:
260, P. 155423 - 155423
Published: June 20, 2024
Curcumin,
the
principal
curcuminoid
of
turmeric
(Curcuma
longa
extract),
is
very
well
known
for
its
multiple
biological
therapeutic
activities,
particularly
anti-inflammatory
and
antioxidant
potential.
However,
due
to
low
water
solubility,
it
exhibits
poor
bioavailability.
In
order
overcome
this
problem,
in
current
study,
we
have
employed
liposomal
technology
encapsulate
curcumin
with
aim
enhancing
efficacy.
The
curcumin-loaded
liposomes
(PlexoZome®)
were
tested
on
a
cigarette
smoke
extract-induced
Chronic
Obstructive
Pulmonary
Disease
(COPD)
vitro
model
using
minimally
immortalized
human
bronchial
epithelial
cells
(BCiNS1.1).
anti-senescence
properties
PlexoZome®
explored.
5
µM
demonstrated
anti-senescent
activity
by
decrease
X-gal
positive
cells,
reduction
expression
p16
p21
immunofluorescence
staining.
Moreover,
also
proteins
related
senescence
(osteopontin,
FGF
basic
uPAR)
inflammation
(GM-CSF,
EGF
ST2).
Overall,
results
clearly
demonstrate
potential
encapsulated
managing
CSE
induced
COPD,
providing
new
direction
respiratory
clinics.
Language: Английский
Exploring Bioactive Phytomedicines for Advancing Pulmonary Infection Management: Insights and Future Prospects
Joyce Siaw Syuen Ho,
No information about this author
Teh Li Ping,
No information about this author
Keshav Raj Paudel
No information about this author
et al.
Phytotherapy Research,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 9, 2024
Pulmonary
infections
have
a
profound
influence
on
global
mortality
rates.
Medicinal
plants
offer
promising
approach
to
address
this
challenge,
providing
nontoxic
alternatives
with
higher
levels
of
public
acceptance
and
compliance,
particularly
in
regions
where
access
conventional
medications
or
diagnostic
resources
may
be
limited.
Understanding
the
pathophysiology
viruses
bacteria
enables
researchers
identify
biomarkers
essential
for
triggering
diseases.
This
knowledge
allows
discovery
biological
molecules
capable
either
preventing
alleviating
symptoms
associated
these
infections.
In
review,
medicinal
that
an
effect
COVID-19,
influenza
A,
bacterial
viral
pneumonia,
tuberculosis
are
discussed.
Drug
delivery
has
been
briefly
discussed
as
well.
It
examines
bioactive
constituents
synthesizes
findings
from
vitro,
vivo,
clinical
studies
conducted
over
past
decade.
conclusion,
many
can
used
treat
pulmonary
infections,
but
further
in-depth
needed
most
current
only
at
preliminary
stages.
Extensive
investigation
warranted
fully
elucidate
their
mechanisms
action
optimize
use
practice.
Language: Английский
Therapeutic Potential of 18-β-Glycyrrhetinic Acid-loaded Poly (lactic-co-glycolic acid) Nanoparticles on Cigarette Smoke-Induced in-vitro model of COPD
Pathology - Research and Practice,
Journal Year:
2024,
Volume and Issue:
263, P. 155629 - 155629
Published: Sept. 28, 2024
Language: Английский